nivolumab sold brand name opdivo medication used treat number types includes melanoma lung cancer malignant pleural mesothelioma renal cell carcinoma hodgkin lymphoma head neck cancer urothelial carcinoma colon cancer esophageal squamous cell carcinoma liver cancer gastric cancer esophageal gastroesophageal junction gej used slow injection common side effects include fatigue rash musculoskeletal pain pruritus itching diarrhea nausea asthenia weakness cough dyspnea shortness breath constipation decreased appetite back pain arthralgia joint pain upper respiratory tract infection pyrexia fever headache abdominal pain use pregnancy may harm nivolumab human monoclonal antibody blocks type immunotherapy works checkpoint inhibitor blocking signal prevents activation cells attacking common side effects used combination chemotherapy include peripheral neuropathy damage nerves outside brain spinal cord nausea fatigue diarrhea vomiting decreased appetite abdominal pain constipation musculoskeletal nivolumab approved medical use united states world health organizations list essential made using chinese hamster ovary nivolumab second fdaapproved systemic therapy first fdaapproved immunotherapy firstline treatment gastric us nivolumab indicated treat nivolumab used firstline treatment inoperable metastatic melanoma combination ipilimumab cancer mutation secondline treatment inoperable metastatic melanoma following treatment ipilimumab cancer braf mutation braf also used treat metastatic squamous nonsmall cell lung cancer progression platinumbased drugs treatment small cell lung also used secondline treatment renal cell carcinoma antiangiogenic treatment nivolumab used primary metastatic urothelial carcinoma common form bladder cancer prescribed locally advanced metastatic form condition experience disease progression following platinumcontaining chemotherapy progression within months neoadjuvant adjuvant treatment platinumcontaining nivolumab indicated adjuvant treatment people melanoma involvement lymph nodes people metastatic disease undergone complete combination nivolumab ipilimumab used firstline treatment adults malignant pleural mesothelioma mpm removed april us food drug administration fda approved nivolumab combination certain types chemotherapy initial treatment people advanced metastatic gastric cancer gastroesophageal junction cancer esophageal may us fda approved nivolumab people completely resected esophageal gastroesophageal junction gej cancer residual pathologic disease received neoadjuvant august us fda approved nivolumab adjuvant treatment people urothelial carcinoma uc high risk recurrence undergoing radical may us fda expanded indication include firstline treatment patients advanced metastatic esophageal squamous cell carcinoma year fda approved combination relatlimab nivolumab opdivo treatment people advanced drug label contains warnings regard increased risks severe immunemediated inflammation lungs colon liver kidneys accompanying kidney dysfunction well immunemediated hypothyroidism hypothyroidism may affect hyperthyroidism autoimmune diabetes similar diabetes mellitus type may occur approximately people treated trials melanoma following side effects occurred subjects frequently chemotherapy alone rash itchy skin cough upper respiratory tract infections peripheral edema clinically important side effects less frequency ventricular arrhythmia inflammation parts eye iridocyclitis infusionrelated reactions dizziness peripheral sensory neuropathy peeling skin erythema multiforme vitiligo trials lung cancer following side effects occurred subjects frequently chemotherapy alone fatigue weakness edema fever chest pain generalized pain shortness breath cough muscle joint pain decreased appetite abdominal pain nausea vomiting constipation weight loss rash itchy levels electrolytes blood cells counts also use pregnancy may harm based data patients terminal halflife nivolumab days steadystate concentrations reached weeks administered mgkg every age gender race baseline ldh expression tumor type tumor size renal impairment mild hepatic impairment affect clearance cells protect body cancer killing certain cancer cells cancer cells evolve proteins protect cells nivolumab blocks protective proteins thus cells kill cancer example immune checkpoint protein surface activated cells another molecule called programmed cell death ligand programmed cell death ligand binds cell becomes inactive one way body regulates immune system avoid many cancer cells make inhibits cells attacking tumor nivolumab blocks binding allowing cell expressed melanomas limited expression otherwise visceral organs exception respiratory epithelium placental nivolumab fully human monoclonal immunoglobulin antibody gamma heavy chain unmodified human design kappa light chain nivolumab generated intellectual property ono pharmaceutical regarding research collaboration entered ono medarexcitation needed research collaboration ono invented medarex using transgenic mice humanized immune system discovery vitro characterization antibody originally called published much later agreement companies medarex held exclusive right nivolumab north america ono retained right countries except north america bristolmyers squibb acquired medarex largely strength checkpoint inhibitor promising clinical trial results made public caused excitement among industry analysts mainstream media avidly pursued biological target time companies including merck pembrolizumab keytruda roche via subsidiary genentech atezolizumab glaxosmithkline collaboration maryland biotech company amplimmune teva collaboration israeli biotech company curetech ono received approval japanese regulatory authorities use nivolumab treat unresectable melanoma july first regulatory approval inhibitor anywhere merck received first fda approval inhibitor pembrolizumab keytruda september nivolumab received fda approval treatment melanoma december april committee medicinal products human use european medicines agency recommended approval nivolumab metastatic melanoma march us fda approved treatment squamous cell lung june european medicines agency ema granted marketing authorization valid throughout european november fda approved nivolumab secondline treatment renal cell carcinoma granted application breakthrough therapy designation fast track designation priority review may fda approved nivolumab treatment patients classical hodgkin lymphoma chl relapsed progressed autologous hematopoietic stem cell transplantation autohsct posttransplantation brentuximab december fda granted approval nivolumab adjuvant treatment melanoma involvement lymph nodes metastatic disease complete april fda granted approval nivolumab combination ipilimumab firstline treatment intermediate poor risk advanced renal cell carcinoma june chinas drug administration approved nivolumab countrys first immunooncology first october us food drug administration fda approved combination nivolumab ipilimumab firstline treatment adults malignant pleural mesothelioma mpm removed april fda approved nivolumab combination certain types chemotherapy initial treatment people advanced metastatic gastric cancer gastroesophageal junction cancer esophageal nivolumab inhibitors appear effective people brain cancer people autoimmune hodgkins lymphoma cells harbor amplification chromosome encodes leads constitutive expression small clinical study published nivolumab elicited objective response rate cohort evidence uncertain effect nivolumab patients hodgkins lymphoma overall survival quality life survival without progression response rate complete disappear grade serious adverse amplification chromosome may serve predictive biomarker hodgkins company pursuing mabs drugs developed assays measure levels potential biomarker using drugs analytespecific reagent assay bms partnered dako nivolumabbased assay however complexity immune response hindered efforts identify people would likely respond well particular levels appear dynamic modulated several factors efforts correlate levels treatment treatment response duration response failed reveal useful correlations bms announced results clinical trial nivolumab failed achieve endpoint better traditional chemotherapy treating newly diagnosed lung bms went attempt win approval combination therapy lung cancer included nivolumab bmss older drug ipilimumab application withdrawn early following disappointing clinical trial infusion times minutes minutes appear similar pharmacokinetics absorption distribution metabolism elimination nivolumab indicated treatment people metastatic squamous non small cell lung cancer nsclc progression platinumbased tested combination nivolumab ipilimumab patients stage iv recurrent nsclc without previous patients expression level randomized ratio receive nivolumab plus ipilimumab nivolumab alone chemotherapy used cisplatin carboplatin combined gemcitabine patient squamous cell nsclc pemetrexed patients nonsquamous overall survival months patients expression level less randomly assigned ratio receive nivolumab plus ipilimumab nivolumab plus chemotherapy os months june bms provided positive fouryear followup results phase study combination nivolumab ipilimumab together chemotherapy compared chemotherapy alone firstline treatment patients metastatic nonsmall cell lung cancer nsclc showing overall survival minimum followup months found patients treated dual immunotherapybased combination alive four years compared patients treated chemotherapy expressed phase ii clinical trials shown nivolumab promising durable treatment option melanoma single agent combination phase iii trials october results phase trial checkmate showed opdivo reduced risk death adjuvant therapy patients completely resected stage two melanoma serious type skin february bms reported threeyear followup results phase trial nivolumab showed significant sustained clinical benefits nivolumab adjuvant treatment patients muscleinvasive urothelial carcinoma high risk recurrence radical immune activation dostarlimab ibalizumab httpsenwikipediaorgwikinivolumab